CombiGene AB (publ) (COMBI.ST)
- Previous Close
2.5600 - Open
2.6000 - Bid 2.4800 x --
- Ask 2.5400 x --
- Day's Range
2.4200 - 2.6000 - 52 Week Range
1.2700 - 4.1200 - Volume
27,685 - Avg. Volume
30,169 - Market Cap (intraday)
49.107M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
www.combigene.comRecent News: COMBI.ST
View MorePerformance Overview: COMBI.ST
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COMBI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COMBI.ST
View MoreValuation Measures
Market Cap
49.11M
Enterprise Value
-24.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
150.63
Price/Book (mrq)
0.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.04%
Return on Equity (ttm)
-47.73%
Revenue (ttm)
3.6M
Net Income Avi to Common (ttm)
-44.88M
Diluted EPS (ttm)
-2.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
73.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.94M